The National Comprehensive Cancer Network® (NCCN) Oncology Research Program (ORP) in collaboration with Pfizer announced this week a list of ten selected organizations and their research projects that have been chosen to receive funding to study the safe, effective, and efficient adoption of biosimilars in oncology:
- American Society of Clinical Oncology, Inc., ASCO’s PracticeNET Learning Network (Analysis of Biosimilar Utilization and Perspectives within ASCO’s PracticeNET Learning Network)
- Baptist Memorial Hospital Tipton (Adoption of Biosimilars in Oncology)
- Cancer Support Community (Frankly Speaking About Cancer: Biosimilars – Researching Oncology Patient and Caregiver Perceptions)
- Cedars-Sinai Medical Center (Optimize Systemic Platform to Assure Quality, Value and Evidence-Based Decision Making on Biosimilar Products Use in Oncology Patients)
- City of Hope Medical Foundation (Challenges to Biosimilar Adoption in Community Oncology Due to Diverse Payer Preferences for Different Biosimilar)
- Houston Methodist (Impact of Discordant Preferred Drug Status between Hospitals and Payers for Chemotherapeutic Biosimilars)
- Roswell Park Comprehensive Cancer Center (Identifying Best Practices in Biosimilar Implementation)
- University of Illinois at Chicago (Developing a Human-Centered Information Packet to Increase Trastuzumab Biosimilars Uptake)
- The University of Texas at Austin (Biosimilar Optimization in Community Oncology Practice)
- UT Southwestern Medical Center (Developing a Clinical Decision Support Tool for Biosimilar Use in Oncology)
According to Wui-Jin Koh, MD, Chief Medical Officer of NCCN, “[t]hese projects will help us to determine best practices for using biosimilars—when safe and appropriate—and how to educate providers and patients about them.”